18F-NaF PET/CT引导下关节腔内阻滞治疗腰椎小关节与骶髂关节病变的疗效与安全性:单臂2期试验
这项单中心、非随机、前瞻性2期试验自2022年8月至2024年6月招募慢性下腰痛患者,对18F-NaF PET/CT显示腰椎小关节或骶髂关节NaF摄取增高者行机器人臂辅助关节腔内阻滞(类固醇加局麻药)。55例接受阻滞者中84%(46/55)在3个月时VAS改善≥50%,无重大不良事件;作者认为在NaF高摄取病变中看似安全可行,但缺乏与标准治疗的比较、样本量小、选择偏倚和辐射暴露限制其推广。
要点
- 85例入组者中79例(92.9%)行18F-NaF PET/CT,61例(77.2%)存在NaF高摄取关节。
- 3个月时84%(46/55)达到VAS改善≥50%的主要终点,未观察到重大不良事件。
核心结论
- 机器人臂辅助18F-NaF PET/CT引导的腰椎小关节和骶髂关节腔内阻滞在NaF高摄取病变的慢性下腰痛患者中看似安全可行。
- 作者指出缺乏与标准治疗的比较、样本量小、选择偏倚和辐射暴露限制其推广。
研究设计与样本
- 单中心、非随机、前瞻性2期临床试验,2022年8月至2024年6月招募慢性下腰痛参与者。
- 入组者在18F-NaF PET/CT上显示腰椎小关节或骶髂关节NaF高摄取后,接受机器人臂辅助关节腔内阻滞(类固醇加局麻药)。
- 记录基线、术后即刻和3个月随访的视觉模拟评分(VAS)、下腰痛结局量表(LBOS)、Oswestry功能障碍指数(ODI)及目标关节SUV变化。
- 主要终点为3个月时VAS改善≥50%,次要终点为ODI改善、LBOS改善至少一个等级及SUV变化。
- 采用描述性统计,定性变量以百分比报告。
主要发现
- 85例入组参与者中79例(92.9%)接受18F-NaF PET/CT检查。
- 79例中61例(77.2%)存在NaF高摄取关节,其中55例(69.6%)接受PET/CT引导机器人臂辅助关节腔内阻滞。
- 主要终点在84%(46/55)参与者中达到,次要终点分别在96%(53/55)和89%(49/55)中达到。
- 操作在所有目标关节中技术成功,治疗后关节术前与术后中位SUVmax和SUVpeak出现显著变化。
- 参与者中未观察到重大不良事件。
局限性
- 缺乏与标准治疗的比较。
- 样本量小。
- 存在选择偏倚。
- 存在辐射暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of robotic-arm-assisted [18F]NaF-PET/CT-guided intra-articular block for lumbar facet joint (LFJ) or sacroiliac joint (SIJ) arthropathy. MATERIALS AND METHODS: In this single-centre, non-randomized, prospective phase 2 clinical-trial, participants with chronic low back pain (CLBP) were recruited from August 2022 to June 2024. Participants having NaF-avid LFJ or SIJ on [18F]NaF-PET/CT underwent robotic-arm-assisted intra-articular block with steroids and local anaesthesia. Baseline, immediate post-procedural, and 3-month follow-up visual analog score (VAS), Low-Back Outcome Scale (LBOS), Oswestry Disability Index (ODI), and change in SUV values of target joints were documented. The primary end-point of the trial was ≥ 50% improvement in VAS at 3 months, and secondary end-points were improvements in ODI, LBOS by at least one grade and change in SUV. Descriptive statistics were applied. Qualitative variables were reported in percentages. RESULTS: Out of 85 enrolled participants, 79 (92.9%) underwent [18F]NaF-PET/CT. Among them, 61 (77.2%) had NaF-avid joints, and 55(69.6%) underwent PET/CT-guided robotic-arm-assisted intra-articular blocks. The primary end-point was met in 84% (46/55) participants, and secondary end-points in 96% (53/55) and 89% (49/55), respectively. The procedure was technically successful in all the target joints. A significant change in pre- and post-procedural median SUVmax and SUVpeak of the treated joints was noticed. No major adverse effects were noticed in the participants. CONCLUSION: Robotic-arm-assisted [18F]NaF-PET/CT guided intra-articular blocks of LFJ and SIJ in CLBP appear to be safe and feasible in NaF-avid arthropathy. However, lack of comparison with the standard of care, small sample size, selection bias and radiation exposure limit its generalizability.
引用
- Kumar R, Krishnaraju VS, Kumar V, et al. Efficacy and safety of [18F]NaF PET/CT guided intraarticular block for lumbar facet joint and sacroiliac joint arthropathy: a single-arm phase 2 trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 40815392. doi:10.1007/s00259-025-07516-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。